Evaluation of a Multimodal Strategy for Early Diagnosis of Men at High Genetic Risk of Prostate Cancer

NCT ID: NCT05333432

Last Updated: 2025-06-25

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: NA
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-01-01
• Study Completion Date: 2026-01-01

Brief Summary

Inherited predisposition to prostate cancer (PC) has been defined by strict clinical criteria or by genetic profile determined by the presence of a deleterious mutation of deoxyribonucleic acid (DNA) repair genes related to breast/ovarian cancers (such as BRCA2, BRCA1) or by PC specific variants (HOXB13 and 8q24CASC19). But currently, recommendations for management and mitigation of PC risk with early screening just emerge for BRCA2 mutation carriers. Our study compares a PC screening strategy based on an annual prostate specific antigen (PSA) test and a clinical examination to a strategy that also includes an annual multiparametric magnetic resonance imaging (mpMRI). It focus not only on 440 unaffected men carrying the BRCA2 mutation, but also on 440 unaffected men member of hereditary PC families with an unidentified mutation or carriers of a mutation of another gene that predisposes to PC, for a total number of participants included of 880. This project estimates the benefits and inconveniences to extend the proposed early diagnosis procedure from unaffected men with BRCA2 mutation to all unaffected men meeting criteria of an inherited predisposition. It should allow to diagnose PC at a more curable stage, and to establish national recommendations for the management of men with high genetic risk of PC useful in clinical routine, depending on typology of the genetic risk. This project aims to efficiently diagnose them, without performing unnecessary biopsies, at curable stage of the disease. It should reduce their risk of death from this cancer known to be of bad prognosis at an advanced stage.

Detailed Description

Hereditary prostate cancer (HPC) has been defined by strict clinical criteria and represents 5% of all newly diagnosed prostate cancers (PC). Inherited predisposition to PC is also genetically determined by the presence of a deleterious mutation of DNA repair genes related to breast/ovarian cancers (BRCA2, BRCA1, ATM,...) or of PC specific variants (HOXB13 and 8q24-CASC19).

According typology of genetic risk, predisposition exposes to an earlier age of onset or a more aggressive form of the disease, increasing the risk of death from this cancer.

Currently, abnormal digital rectal examination (DRE) and PSA level above 4ng/mL are validated as an indication for performing a MRI and prostate biopsies to establish PC diagnosis in its frequent sporadic form. Recommendations for the management and the mitigation of PC risk with early screening just emerge for BRCA2 mutation carriers.

The unaffected relatives from these HPC families and the carriers of these mutations are potentially at higher risk of PC and need a dedicated screening procedure.

This project is based on our experience and the results from the international IMPACT study.

Our study will compare this PC screening strategy based on an annual PSA test and a clinical examination to a strategy that also includes an annual multiparametric MRI (mpMRI). Indeed, the PROMIS study has shown that mpMRI is very efficient to detect aggressive PC (sensitivity: 93%), and can identify PC in men with low PSA value. This project will estimate the benefits and inconveniences to extend mpMRI at unaffected men with BRCA2 mutation and potentially to all unaffected men meeting criteria of an inherited predisposition. It should allow to diagnose PC at a more curable stage, and to establish national recommendations for the management of men with high genetic risk of PC useful in clinical routine, depending on typology of the genetic risk.

Indeed, the last French national recommendations (HAS "Haute Autorité de Santé" 2012) in terms of systematic screening for prostate cancer do not include men at high genetic risk. Regarding populations of men at high risk, the HAS indicates that in the current state of knowledge, firstly, identifying the groups of men at higher risk of developing prostate cancer is not in itself sufficient to justify screening; and secondly, that no scientific evidence has been found to justify screening for prostate cancer by assaying PSA in male populations considered to be at higher risk of prostate cancer. But these recommendations were published before the results obtained by the IMPACT study.

The study focuses on 880 unaffected men at high genetic risk of PC: 440 unaffected men carrying the BRCA2 mutation, and also 440 unaffected men member of hereditary PC families with an unidentified mutation or carriers of a mutation of another gene that predisposes to PC.

Participants are pre-screened by the investigators among the files of participants already followed by the urology and/or oncogenetic department. Potential participants of the study have been already identified because they are carrying the BRCA2 mutation or are a member of hereditary PC families with an unidentified mutation or carriers of a mutation of another gene that predisposes to PC. Screened participants are offered to participate to the study by the urologist or the oncogenetic, during a consultation visit which constitutes the inclusion visit.

After the inclusion visit, participants undergo annual follow-up consultation visits, as in standard care, during 3 years.

Each follow-up visit consists of :

• an urologic consultation (clinical examination (DRE) and PSA test)
• a MRI examination The urologic consultation and the MRI examination are scheduled from one year to the next by the urologist.

Radiologists perform MRI, interpret MRI according to the PIRADS-V2 classification and organize the anonymous export of the MRI for centralized review within 15 days of the MRI examination. One of the three referent expert radiologists perform the review of the MRI images, within a week. In case of disagreement between the local and expert interpretations, a third review is performed by one of the two other referent expert radiologists to conclude. In case of disagreement between the 2 expert radiologists, the highest PIRADS-V2 is considered.

In case of abnormal DRE or PSA > 3ng/mL or PIRADS-V2 > 2 on mpMRI, a prostatic biopsy has to be performed as in routine care. The participant continues to be followed by the investigator until the results of biopsy are obtained:

• If PC is diagnosed from biopsies, the referent pathologist of the clinical center makes a standardized report of the pathological analysis of the diagnostic biopsies and organizes anonymous export of scanned slides for centralized review. Two expert pathologists, while blinded to clinical, biological and radiological datas perform the centralized review of positive biopsies at the end of the study. Prostate biopsy pathological analysis are assessed according national referential using International Society of Urological Pathology (ISUP) scoring. The participant then leaves the study prematurely and the date of premature discontinuation is the biopsy date.
• If biopsy is negative, the participant remains enrolled in the study and pursue his annual follow-up.

The result of the study is to be compared to the interim results of the IMPACT study obtained after 3 years of screening (DRE & PSA test) on non affected men carrying or not BRCA2 mutation.

Conditions

Prostate Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Men at high genetic risk of prostate cancer

Cohort of unaffected men from 40 to 70 years olds with high risk of prostate cancer (PC) defined as being a member from a family that meets hereditary PC criteria or by carrying a mutation of a DNA repair gene or a gene specific to PC.

Group Type: OTHER

Multiparameric MRI with injection

Intervention Type: PROCEDURE

Participants have a prostate multiparametric MRI with gadolinium injection (T2, diffusion and perfusion sequences) every year.

PIRADS-V2 is used as decisional endpoint, and subjective score LIKERT as secondary analysis.

To compute sensivity and specificity, we consider LIKERT as suspicious and/or malignant (PIRADS-V2 = 3, 4 or 5) as positive.

Interventions

Multiparameric MRI with injection

Participants have a prostate multiparametric MRI with gadolinium injection (T2, diffusion and perfusion sequences) every year.

PIRADS-V2 is used as decisional endpoint, and subjective score LIKERT as secondary analysis.

To compute sensivity and specificity, we consider LIKERT as suspicious and/or malignant (PIRADS-V2 = 3, 4 or 5) as positive.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Unaffected men at high genetic risk of prostate cancer (PC) defined as being a member from a family that meets hereditary PC criteria or by carrying a mutation of a DNA repair gene (BRCA1 / BRCA2 / CDH1 / MLH1 / MSH2 / MSH6 / PALB2 / PTEN / RAD51C / RAD51D / TP53 / ATM / BARD1 / BLM / BRIP1 / CHEK2 / MRE11A / MLH3 / NBN / RAD50 / STK11) or a gene specific to PC (HOXB13 / 8q24-CASC19)
• Aged between 40 and 70 years old
• Written informed consent signed by the participant
• Affiliated to the social security system

Exclusion Criteria

• Contraindication for MRI (any foreign metallic bodies: cardiac implantable electronic device (CIED) such as pacemakers, implantable cardioverter defibrillators (ICDs) etc., metallic intraocular foreign bodies, implantable neurostimulation systems, cochlear implants/ear implant, drug infusion pumps (insulin delivery, analgesic drugs, or chemotherapy pumps): If possible, the participant has to remove the device. catheters with metallic components (Swan-Ganz catheter), metallic fragments such as bullets, shotgun pellets, and metal shrapnel , cerebral artery aneurysm clips, magnetic dental implants, tissue expander, artificial limb, hearing aid , piercing, clostrophobia, contrast agents allergy or any other contraindication to contrast agents and to their excipients)
• Treatment with a drug that changes PSA level such as 5 alpha reductase inhibitors (dutastéride, finasteride),
• Prostatic biopsy during the last 2 years, or other progressive cancer or co-morbidities threatening survival at 10 years
• Participant under tutorship or / guardianship, and incapable to give informed consent
• Participation to another interventional clinical trial

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute, France

OTHER_GOV

Sponsor Role: collaborator

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Pierre MONGIAT-ARTUS, PUPH

Role: STUDY_DIRECTOR

Department of Urology - Hôpital Saint Louis - APHP Sorbonne Université

References

Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham AP, Oldroyd R, Parker C, Emberton M; PROMIS study group. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017 Feb 25;389(10071):815-822. doi: 10.1016/S0140-6736(16)32401-1. Epub 2017 Jan 20.

Reference Type: BACKGROUND

PMID: 28110982 (View on PubMed)

Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, Taylor N, Chamberlain A, Pope J, Raghallaigh HN, Evans DG, Rothwell J, Maehle L, Grindedal EM, James P, Mascarenhas L, McKinley J, Side L, Thomas T, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Jensen TD, Osther PJS, Helfand BT, Genova E, Oldenburg RA, Cybulski C, Wokolorczyk D, Ong KR, Huber C, Lam J, Taylor L, Salinas M, Feliubadalo L, Oosterwijk JC, van Zelst-Stams W, Cook J, Rosario DJ, Domchek S, Powers J, Buys S, O'Toole K, Ausems MGEM, Schmutzler RK, Rhiem K, Izatt L, Tripathi V, Teixeira MR, Cardoso M, Foulkes WD, Aprikian A, van Randeraad H, Davidson R, Longmuir M, Ruijs MWG, Helderman van den Enden ATJM, Adank M, Williams R, Andrews L, Murphy DG, Halliday D, Walker L, Liljegren A, Carlsson S, Azzabi A, Jobson I, Morton C, Shackleton K, Snape K, Hanson H, Harris M, Tischkowitz M, Taylor A, Kirk J, Susman R, Chen-Shtoyerman R, Spigelman A, Pachter N, Ahmed M, Ramon Y Cajal T, Zgajnar J, Brewer C, Gadea N, Brady AF, van Os T, Gallagher D, Johannsson O, Donaldson A, Barwell J, Nicolai N, Friedman E, Obeid E, Greenhalgh L, Murthy V, Copakova L, Saya S, McGrath J, Cooke P, Ronlund K, Richardson K, Henderson A, Teo SH, Arun B, Kast K, Dias A, Aaronson NK, Ardern-Jones A, Bangma CH, Castro E, Dearnaley D, Eccles DM, Tricker K, Eyfjord J, Falconer A, Foster C, Gronberg H, Hamdy FC, Stefansdottir V, Khoo V, Lindeman GJ, Lubinski J, Axcrona K, Mikropoulos C, Mitra A, Moynihan C, Rennert G, Suri M, Wilson P, Dudderidge T; IMPACT Study Collaborators; Offman J, Kote-Jarai Z, Vickers A, Lilja H, Eeles RA. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. Eur Urol. 2019 Dec;76(6):831-842. doi: 10.1016/j.eururo.2019.08.019. Epub 2019 Sep 16.

Reference Type: BACKGROUND

PMID: 31537406 (View on PubMed)

Other Identifiers

APHP210359

Identifier Type: -

Identifier Source: org_study_id